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Background: Metastases-directed therapy (MDT) with surgery or stereotactic body radiotherapy (SBRT) is emerging as
a new treatment option for prostate cancer (PCa) patients with a limited number of metastases (≤3) at recurrence – so
called “oligometastases”. One of the goals of this approach is to delay the start of palliative androgen deprivation
therapy (ADT), with its negative impact on quality of life. However, the lack of a control group, selection bias and the
use of adjuvant androgen deprivation therapy prevent strong conclusions from published studies.
The aim of this multicenter randomized phase II trial is to assess the impact of MTD on the start of palliative ADT
compared to patients undergoing active surveillance.
Methods/Design: Patients with an oligometastatic recurrence, diagnosed on choline PET/CT after local treatment with
curative intent, will be randomised in a 1:1 ratio between arm A: active surveillance only and arm B: MTD followed by
active surveillance. Patients will be stratified according to the location of metastasis (node vs. bone metastases) and PSA
doubling time (≤3 vs. > 3 months). Both surgery and SBRT are allowed as MDT. Active surveillance means 3-monthly PSA
testing and re-imaging at PSA progression. The primary endpoint is ADT-free survival. ADT will be started in both arms at
time of polymetastatic disease (>3 metastatic lesions), local progression or symptoms. The secondary endpoints include
progression-free survival, quality of life, toxicity and prostate-cancer specific survival.
Discussion: This is the first randomized phase 2 trial assessing the possibility of deferring palliative ADT with MDT in
oligometastatic PCa recurrence.
Trial registration: Clinicaltrials.gov identifier: NCT01558427
Keywords: Oligometastases, Prostate cancer, Salvage treatment, Stereotactic body radiotherapy, Salvage lymph node
dissection, Active surveillance, Androgen deprivation therapy, Quality of life, SurvivalBackground
Prostate cancer (PCa) is the most frequent tumour in
males and PCa death is attributed to metastatic disease
in the majority of patients [1]. The first line treatment of
metastatic PCa is lifelong androgen deprivation therapy
(ADT) by means of surgical or medical castration [1].
Although this strategy delays PCa progression, it is asso-
ciated with numerous side effects impacting quality-of-* Correspondence: piet.ost@ugent.be
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article, unless otherwise stated.life and general health [2,3]. There is no proven overall
survival benefit of immediate ADT over deferred ADT
in metastatic patients [1]. It is therefore an option in the
EAU guidelines to suggest an active surveillance proto-
col for well-informed asymptomatic patients with PCA
metastases [1].
In analogy with other solid tumours, eradication of these
oligometastases by means of metastases directed therapy
(MDT) with stereotactic body radiotherapy (SBRT) or sur-
gery is a promising and emerging way to delay disease pro-
gression and postpone systemic treatment without majorentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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plicate assessment of the benefit of radical treatment for
oligometastastatic prostate cancer recurrence.
Firstly, the identification of patients with oligometastatic
disease is challenging. The traditional imaging studies
such as bone scan and computed tomography lack suffi-
cient sensitivity to detect low volume metastatic disease at
low PSA levels [5]. Consequently, these imaging modal-
ities are not recommended to screen patients for metasta-
ses until the PSA reaches 10 ng/ml19. Choline positron
emitting tomography (PET) with computed tomography
(CT) might be a good candidate for the identification of
low volume metastases with a pooled sensitivity and speci-
ficity exceeding 85% on a per-patient basis in the recurrent
setting [6,7].
Secondly, the apparent achievement of MDT for oligome-
tastatic PCa in postponing palliative ADT and in slowing
down progression has only been observed in single arm
studies [8,9]. The true benefit of this MDT can only be
assessed through randomization versus a control group.
Otherwise, it could be that the promising results are only
due to selection of fit patients with very slow-growing tu-
mors, rather than the result of treatment intervention itself.
The current study will address these shortcomings by
randomizing MDT versus active surveillance. The active
surveillance arm will inform us about the natural pro-
gression of oligometastatic PCa.
This study is the first randomized study in this setting
and will employ a randomized phase II design to deter-
mine which arm is justified to be tested in a subsequent
phase III trial.
Methods/design
This study is approved by the Ethics committee of the
Ghent University Hospital (EC2012/156) and is regis-
tered on clinicaltrials.gov (NCT01558427). The protocol
is designed according to the clinical-state model [10]:
rising PSA and clinical metastases state in non-castrate
patients. Patients diagnosed with oligometastases (up to
3 N1 or M1a/b lesions [1]) will be entered in a random-
ized Phase II trial. In the experimental arm A, patients
will undergo active clinical surveillance with the start of
ADT at progression. In arm B, patients will receive SBRT
or surgery of the oligometastases, followed by active
clinical surveillance.
Objectives
– Primary endpoint
○ Androgen deprivation therapy free survival
ADT will be started in both arms at time of
polymetastatic disease, local progression (defined
below) or symptoms. In case of a metachronous
oligometastatic recurrence in arm A, aretreatment with radiotherapy or surgery is
allowed. Calculation will start from
randomization until ADT is started.– Secondary endpoints
○ Quality of life scoring using the EORTC
QLQ-C30 supplemented with QLQ-PR25. Raw
scores will be transformed to a linear scale
ranging from 0 to 100. The results will be
presented in accordance with recent guidelines
for reporting HRQOL RCTs [11].
○ Assessment of quality-adjusted-life-years
with the EuroQol classification system (EQ-5D)
[12]. A written consent to use this system has
been obtained from the EuroQol Group
Foundation.
○ Acute and late toxicity due to radiotherapy
will be scored using the Common toxicity
criteria version 4.0 [13]. Surgical complications
will be scored using Clavien-Dindo Classification
[14]. Other surgical related morbidity (intra-op-
erative complications (blood loss, injury to pelvic
or intra-abdominal organs…) and duration of
hospital stay) will also be recorded.
○ Time to castration-resistant disease is
calculated from randomization until develop-
ment of castration-resistant disease as defined by
the EAU guidelines [1].
○ Progression-free survival:
▪ 3 types of progression are defined
and definitions of progression are used and
registered according to the recommendations
of the prostate cancer clinical trials working
group [10]. Calculation will start from
randomization until progression or death.
▪ PSA or biochemical progression:
 In case of decline from baseline: record time
from randomization to first PSA increase that
is ≥25% and ≥ 2 ng/ml above the nadir OR
that is ≥25% and rises above the pre-
treatment PSA value and which is confirmed
by a second value 3 or more weeks later.
 In case of no decline from baseline: PSA
increase that is ≥25% and ≥ 2 ng/ml after
3 months if baseline PSA is ≥2 ng/ml. PSA
increase that is ≥25% after 3 months if
baseline PSA is < 2 ng/ml.
 Local progression for soft-tissue and bone
lesions: Each metastasis is a target lesion
independently assessed for response with the
RECIST criteria [15]. In addition, metastases
(particularly osseous) with a metabolic
complete response on bone or PET scan are
scored as complete response in the absence
of progression on CT scan.
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new metastatic lesions.
 Prostate cancer specific survival will be
calculated from randomization until PCa
death. Overall survival will be calculated from
randomization until death from any cause.
 Time to first symptomatic event will be
calculated from randomization until the
event of symptoms due to metastatic disease.Inclusion criteria
– Histologically proven diagnosis of PCa
– PCa patients with a biochemical recurrence
following treatment with curative intent (radical
prostatectomy, primary radiotherapy or a
combination of both) as defined by the EAU
guidelines [1].
– A maximum of 3 extracranial metastases in any
organ system diagnosed on choline PET-CT.
– Controlled primary tumor
○ Patients in the postoperative setting should
have received postoperative radiotherapy to the
prostate bed. In case the PSA > 2 ng/ml in the
postoperative setting patients are eligible if a
multiparametric MRI of the prostate bed rules
out a local relapse or a negative biopsy of the
prostate bed is performed37. Patients after
primary radiotherapy should undergo MRI of
the prostate according to the European Society
of Urogenital Radiology (ESUR) guidelines to
rule out local relapse [16]. In case of a
suspicious lesion, a biopsy should confirm local
recurrence and patients should be referred for
local salvage prostatectomy when distant
metastases are ruled out. If MRI rules out local
relapse, patients are eligible.
– WHO performance state 0-1
– Age ≥18 years old
– Willing to provide a signed informed consent
– Patient presented at the multidisciplinary tumour
board of the local hospital in which the therapy will
be given.
Exclusion criteria
– Serum testosterone level <50 ng/ml
– Symptomatic metastases
– Patients with oligometastases that have been
previously treated.
– PSA rise while on active treatment (LHRH-agonist,
LHRH-antagonist, anti-androgen, maximal androgen
blockade, oestrogen)
– Previous treatment with a cytotoxic agent for PCa– Treatment during the past month with products
known to influence PSA levels (e.g. fluconazole,
finasteride, corticosteroids,…)
– Disorder precluding understanding of trial
information or informed consent
Evaluation and randomization
Patients must be restaged within 4 weeks prior to
randomization with 18F or 11C-choline PET-CT. MRI full
spine and bony pelvis or MRI whole body is optional, but
recommended in case of equivocal findings. Bone scintig-
raphy is not required.
The study will employ a 1:1 randomization between
arm A: arm B. Patients will be stratified according to
PSA doubling time and (≤3 vs. > 3 months) and initial
localization of metastases (node vs bone or visceral).
Interventions
1. Arm A: Active clinical surveillance
– Defined as 3-monthly clinical examination and
serum PSA measurement. Restaging will be
performed in case of symptomatic progression or
PSA progression:
▪ A PSA increase that is ≥25% and ≥ 2 ng/ml
if baseline PSA is ≥2 ng/ml.
▪ A PSA increase that is ≥25% if baseline
PSA is < 2 ng/ml.
– ADT will be started at time of polymetastatic
disease, local progression (defined above) or
symptoms. The type of ADT is left to the
discretion of the treating physician. Both
anti-androgen monotherapy, LHRH agonist or
antagonists and maximal androgen deprivation
therapy are allowed. Both intermittent and
continuous ADT are allowed.
2. Arm B
a. SBRT and surgery.All patients randomized into arm A will be
presented at the multidisciplinary urology
tumour board prior to treatment. The
choice between SBRT or surgery will depend
on localization and size of the metastases,
the nearby organs-at-risk and previous treat-
ments in the vicinity of the metastases. After
reaching a consensus, the patient will be in-
formed about the options for treatment.b. SBRT target and organ-at-risk definition.
All patients will receive a CT simulation in
supine position with 2 mm CT slice
thickness through the tumour site. The
planning simulation should cover the target
and all organs at risk. A typical scan length
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inferior beyond the treatment field borders.
Support devices to increase patient comfort
will be chosen depending on the tumour
localisation. The isocenter will be determined
on the CT-simulator with marking of laser
lines on the patient. Imaging data will be
transferred to the treatment planning system.
For all lesions, the Gross Target Volume
(GTV) will be defined as all visible tumor by
combining iconographic and metabolic
information. No additional margin will be
added for microscopic spread of disease.
The GTV will be expanded with 2-5 mm to
the Planning Target Volume (PTV) to
account for organ motion and setup error.
Margins depend on the site irradiated with
2 mm margins for bony lesions, 3 mm for
nodes and 5 mm for other sites. The type of
organ at risk delineated depends on the
localization of the metastasis. A Planning
Organ at Risk Volume (PRV) expansion of
2-5 mm will be added for OAR such as the
spinal cord, oesophagus, intestine,… (if applic-
able), and dose constraints apply to this
PRV. It is strongly recommended that dose
constraints not be exceeded. If a dose
constraint cannot be achieved due to
overlap of the target with an organ at risk
or its PRV, the total dose can be lowered in
order to meet the constraint.
For spinal lesions, a pre-treatment axial MRI
is required to assess the extent of disease
and position of the cord. This must be fused
with the planning CT scan.c. Radiotherapy treatment planning and dose
prescription:
IMRT (static or rotational) treatment
planning will be dependent the localization
of the metastasis. Dose constraints for organ
at risks will be in accordance with the
recommendations from the report of the
AAPM task group 101 [17]. A total dose of
30 Gy (80% of the maximal dose) will be
delivered in 3 fractions and fractions will be
separated >48 h and <96 h [18,19].
Treatment will be prescribed to the
periphery of the target (80% of the dose
(=30 Gy), should cover 90% of the PTV). In
case of violation of dose constraints to the
organs at risk, the prescription will be
adapted accordingly. If multiple targets will
be irradiated and the targets are more than
10 cm apart in the cranio-caudal direction,multiple isocenters are needed with a CBCT
prior to every treatment for every isocenter.
Patient immobilization devices can be used
according to the institutional policy.d. Radiotherapy delivery and verification:
In order to ensure patient safety and
effective treatment delivery the following
measurements are taken:
– Prior to treatment, all plans are discussed
and approved at the daily radiotherapy
rounds after prior verification by the
treating physician.
– All dose delivery for intensity-modulated
plans will be confirmed before treatment
by physics staff.
– At each fraction, a cone-beam CT (CBCT)
will be used for patients’ set-up and target
verification prior to treatment. In case of
multiple isocenters, every isocenter will be
verified separately with CBCT.
– Quality assurance: all plans will be
verified using the Delta(4) diode array
phantom prior to treatment delivery [20].e. Surgical procedures:
The surgical technique to be used is at the
discretion and expertise of the surgeon but
must be in accordance to the best surgical
practice available. A minimally invasive
technique is preferred, but not obligatory.
For pelvic nodal metastases, in case of a
previous extended pelvic lymph node
dissection (ePLND) or pelvic radiotherapy,
only the suspicious lymph node will be
removed. If no ePLND has been performed
previously, a salvage ePLND will be
preferred. In case of retroperitoneal nodes,
only the suspicious node will be removed.f. Androgen deprivation therapy:
ADT will be started as in arm A. In case of
a metachronous oligometastatic
recurrence, a retreatment with SBRT
or surgery is allowed.Follow-up
Patients will be seen every 3 months post-randomization
(Table 1). At each visit, a history and physical exam-
ination will conducted with recording of the toxicity.
The QOL questionnaires will be concluded at each
visit. Choline PET-CT will be repeated at PSA or
symptomatic progression. Additional Imaging or la-
boratory investigations should be carried out at the
discretion of the treating physician, based on findings
in the history or physical, and additional treatment
(e.g. ADT).
Table 1 Study visits and procedures
At inclusion 3-monthly At PSA or
symptomatic
progression
Eligibility check *
Informed consent *
PET-CT * *
QOL questionnaire * * *
Toxicity assessment * * *
PSA measurement * * *
History and physical
examination
* * *
*reflects the timepoint of a certain assessment.
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Sample size
This study will employ a randomized phase II design to
determine which arm is justified to be tested in a subse-
quent phase III trial. The study will therefore be de-
signed with an alpha and beta = 0.20 (as recommended
for phase II randomized trials [21,22]). It is estimated
that the median delay to start palliative ADT after
metastasis-directed therapy is approximately 24 months
[4]. There will be a 1:1 randomization between Arm 1
and Arm 2. Patients will be stratified according to PSA
doubling time (≤3 vs. > 3 months) and initial localization
of metastases (node vs bone or visceral). In order to de-
tect a 12-month difference in the studied endpoint from
12 to 24 months, a total of 58 patients will be needed.
Assuming a 5% rate of loss to follow-up, a total of 62 pa-
tients will be accrued over 36 months with 12 months of
additional follow-up. We expect an accrual rate of 20
patients per year.Data analysis
Patients will be analysed in the groups to which they are
assigned (intention-to-treat). The primary endpoint an-
drogen deprivation therapy-free survival will be calcu-
lated using Kaplan-Meier actuarial analyses. Pre-planned
subgroup analysis will occur based on stratification vari-
ables using the log-rank test. Survival times are defined
from the day of randomization until an event (start of
ADT) or last follow-up. Cases will be censored at last
follow up visit if no ADT was started. Multivariate ana-
lysis will be performed according to the Cox-Regression
method.
Overall survival and progression-free survival (local,
biochemical and clinical progression free survival) will
be evaluated in the same way as the primary endpoint.
All p values are set at 0.05. Statistical analysis will be
performed with SPSS (IBM Corp, Somers, NY, USA).Discussion
The standard treatment options for PCa patients diagnosed
with metastatic progression following primary treatment
have remained unchanged over the past years [23], with
ADT being the cornerstone of treatment [1]. Several small,
single arm observational studies have been reported with
promising results [4,8,9,19,24-26]. However the rather ran-
dom use of a multimodality approach with adjuvant ADT
and prophylactic nodal irradiation in these studies makes it
difficult to make any definite conclusions. This is the first
randomized phase 2 trial that will asses the possibility of
deferring palliative ADT and cancer progression with
MDT by means of SBRT or surgery. The inclusion of an
active surveillance arm will improve our insights in the
natural progression of oligometastatic PCa.
Abbreviations
PCa: Prostate cancer; ADT: Androgen deprivation therapy; EAU: European
Association of Urology; PET-CT: Positron emission tomography;
CT: Computed tomography; MRI: Magnetic resonance imaging; AS-MRI:
Axial skeleton MRI; WB-MRI: Whole body MRI; PSA: Prostate specific antigen;
SBRT: Stereotactic body radiotherapy; ePLND: Extended pelvic lymph node
dissection; IMRT: Intensity modulated radiotherapy; AAPM: American
Association of Physicists in Medicine; GTV: Gross target volume; PTV: Planned
target volume; PRV: Planning organs at risk volume; RT: Radiotherapy;
QOL: Quality of life; EORTC: European Organization for Research and
Treatment of Cancer; RTOG: Radiation Therapy Oncology Group; WHO: World
Health Organization; ESUR: European Society of Urogenital Radiology;
LHRH: Luteinizing hormone releasing hormone.
Competing interests
The authors declare that they have no competing interests.
Author’s contributions
Study conception: GD, PO. Initial Study design: PO, GD, KD, NL, GV, BL,
Revision of study design and protocol: PO, GD, KD, NL, LD, VF, GV, WH, BL.
Study coordination: PO, KD. Participating centers: WD, FA, IB, SaJ, StJ, PS.
Drafting the manuscript: all authors. All authors read and approved the
final manuscript.
Acknowledgements
This study is funded by a grant of the Vlaamse Liga tegen Kanker (VLK).
The granting bodies are not involved in data collection or analysis.
Dr. Piet Ost is a senior Clinical Investigator of the Research Foundation - Flanders
(Belgium) (FWO).
Author details
1Department of Urology, Ghent University Hospital, Ghent, Belgium.
2Department of Radiotherapy, Ghent University Hospital, Ghent, Belgium.
3Department of Urology, AZ Maria Middelares Gent, Ghent, Belgium.
4Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.
5Department of Urology, University Hospitals Leuven, Leuven, Belgium.
6Department of Radiology, Ghent University Hospital, Ghent, Belgium.
7Department of Urology, AZ Groeninghe, Kortrijk, Belgium. 8Department of
Radiotherapy, AZ Sint-Lucas Gent, Ghent, Belgium. 9Department of
Radiotherapy, CH Mouscron, Mouscron, Belgium.
Received: 6 June 2014 Accepted: 2 September 2014
Published: 15 September 2014
References
1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason
M, Matveev V, Wiegel T, Zattoni F, Mottet N: EAU guidelines on prostate cancer.
part II: treatment of advanced, relapsing, and castration-resistant prostate
cancer. Eur Urol 2014, 65(2):467–479.
Decaestecker et al. BMC Cancer 2014, 14:671 Page 6 of 6
http://www.biomedcentral.com/1471-2407/14/6712. Abrahamsson PA: Potential benefits of intermittent androgen
suppression therapy in the treatment of prostate cancer: a systematic
review of the literature. Eur Urol 2010, 57(1):49–59.
3. Taylor LG, Canfield SE, Du XL: Review of major adverse effects of
androgen-deprivation therapy in men with prostate cancer. Cancer 2009,
115(11):2388–2399.
4. Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T,
De Vos F, Huysse W, Ost P: Repeated stereotactic body radiotherapy for
oligometastatic prostate cancer recurrence. Radiat Oncol 2014, in press.
5. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP,
Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU guidelines on
prostate cancer. part II: treatment of advanced, relapsing, and
castration-resistant prostate cancer. Eur Urol 2011, 59(4):572–583.
6. Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM: The role of
11C-choline and 18 F-fluorocholine positron emission tomography (PET)
and PET/CT in prostate cancer: a systematic review and meta-analysis.
Eur Urol 2013, 64(1):106–117.
7. Wondergem M, van der Zant FM, van der Ploeg T, Knol RJ: A literature
review of 18 F-fluoride PET/CT and 18 F-choline or 11C-choline PET/CT
for detection of bone metastases in patients with prostate cancer.
Nucl Med Commun 2013, 34(10):935–945.
8. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N,
Decaestecker K, Villeirs G, Vuye P, Ost P: Salvage stereotactic body
radiotherapy for patients with limited prostate cancer metastases:
deferring androgen deprivation therapy. Clin Genitourin Cancer 2013,
11(1):27–32.
9. Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D,
Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F,
Briganti A: Long-term outcomes of salvage lymph node dissection for
clinically recurrent prostate cancer: results of a single-institution series
with a minimum follow-up of 5 years. Eur Urol 2014,
doi:10.1016/j.eururo.2014.02.011.
10. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA,
Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch
E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M,
Prostate Cancer Clinical Trials Working Group: Design and end points of
clinical trials for patients with progressive prostate cancer and castrate
levels of testosterone: recommendations of the Prostate Cancer Clinical
Trials Working Group. J Clin Oncol 2008, 26(7):1148–1159.
11. Bottomley A, Flechtner H, Efficace F, Vanvoorden V, Coens C, Therasse P,
Velikova G, Blazeby J, Greimel E, European Organisation for Research and
Treatment of Cancer: Health related quality of life outcomes in cancer
clinical trials. Eur J Cancer 2005, 41(12):1697–1709.
12. EuroQol Group: EuroQol–a new facility for the measurement of
health-related quality of life. the EuroQol Group. Health Policy 1990,
16(3):199–208.
13. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C,
Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development
of a comprehensive grading system for the adverse effects of cancer
treatment. Semin Radiat Oncol 2003, 13(3):176–181.
14. Mitropoulos D, Artibani W, Graefen M, Remzi M, Roupret M, Truss M:
Reporting and grading of complications after urologic surgical
procedures: an ad hoc EAU guidelines panel assessment and
recommendations. Eur Urol 2012, 61(2):341–349.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,
Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L,
Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009,
45(2):228–247.
16. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G,
Rouviere O, Logager V, Futterer JJ, European Society of Urogenital
Radiology: ESUR prostate MR guidelines 2012. Eur Radiol 2012,
22(4):746–757.
17. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall
P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B,
Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tome
WA, Verellen D, Wang L, Yin FF: Stereotactic body radiation therapy: the
report of AAPM Task Group 101. Med Phys 2010, 37(8):4078–4101.
18. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor
VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE,
Hellman S, Weichselbaum RR: Stereotactic body radiotherapy for multisiteextracranial oligometastases: final report of a dose escalation trial in
patients with 1 to 5 sites of metastatic disease. Cancer 2012,
118(11):2962–2970.
19. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M,
Gulisano M, Aterini S: Efficacy of eradicative radiotherapy for limited
nodal metastases detected with choline PET scan in prostate cancer
patients. Tumori 2011, 97(1):49–55.
20. Bedford JL, Lee YK, Wai P, South CP, Warrington AP: Evaluation of the
Delta4 phantom for IMRT and VMAT verification. Phys Med Biol 2009,
54(9):N167–N176.
21. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA: Design
issues of randomized phase II trials and a proposal for phase II screening
trials. J Clin Oncol 2005, 23(28):7199–7206.
22. Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, Olson
R, Liu M, Panarotto J, Griffioen GH, Gaede S, Slotman B, Senan S:
Stereotactic ablative radiotherapy for comprehensive treatment of
oligometastatic tumors (SABR-COMET): study protocol for a randomized
phase II trial. BMC Cancer 2012, 12:305.
23. Palmbos PL, Hussain M: Non-castrate metastatic prostate cancer: have the
treatment options changed? Semin Oncol 2013, 40(3):337–346.
24. Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, Drendel V,
Schwardt M, Jandausch A, Schultze-Seemann W: Salvage lymph node dis-
section with adjuvant radiotherapy for nodal recurrence of prostate can-
cer. J Urol 2012, 188(6):2190–2197.
25. Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, Ratib O, Weber DC,
Miralbell R: Androgen deprivation and high-dose radiotherapy for
oligometastatic prostate cancer patients with less than five regional
and/or distant metastases. Acta Oncol 2013, 52(8):1622–1628.
26. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A,
Zerini D, Gherardi F, Ascione C, Bossi-Zanetti I, Mauro R, Bregantin A, Bianchi LC,
De Cobelli O, Orecchia R: Robotic image-guided stereotactic radiotherapy, for
isolated recurrent primary, lymph node or metastatic prostate cancer. Int J
Radiat Oncol Biol Phys 2012, 82(2):889–897.
doi:10.1186/1471-2407-14-671
Cite this article as: Decaestecker et al.: Surveillance or metastasis-
directed Therapy for OligoMetastatic Prostate cancer recurrence
(STOMP): study protocol for a randomized phase II trial. BMC Cancer
2014 14:671.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
